University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of breast health services, today announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk.
Less Waste, More Doses, No Anti-Rejection Drugs: SymbioCellTech NEO-ISLETS(TM) Utilization of Donor Organs, Tissue
Insulin is a hormone that allows the body to deliver sugar to the cells which they use for energy. Type 1 Diabetes Mellitus (T1DM) is a disorder in which the insulin producing cells in the pancreas are attacked and killed by the patient’s own immune system. Without this ability, even though the person eats sugar, it cannot get to the cells, but remains in the blood, and the cells starve and die. For T1DM patients, insulin injections are life-saving, but cannot prevent the development of serious diabetic complications such as blindness, kidney failure, strokes, heart attacks, amputations, premature births and deaths. In an article for the August 24 issue of PLOS ONE, SymbioCellTech (SCT) reports significant success using human Neo-Islets created from suboptimal donors and donor tissues in the treatment of T1DM.